US EPA

7941680 

Journal Article 

Antimyoclonic effect of gabapentin in a posthypoxic animal model of myoclonus 

Kanthasamy, AG; Vu, TQ; Yun, RJ; Truong, DD 

1996 

1 

European Journal of Pharmacology
ISSN: 0014-2999
EISSN: 1879-0712 

297 

3 

219-224 

English 

8666053 

10.1016/0014-2999(95)00741-5 

WOS:A1996TX91300004 

The antimyoclonic property of the novel antiepileptic drug, gabapentin (1-(aminomethyl) cyclohexane acetic acid), was tested in cardiac arrest-and p,p'-DDT(1,1,1-trichloro-2,2-bis (p-chlorophenyl)ethane)-induced animal models of myoclonus. Gabapentin dose-dependently attenuated myoclonus in posthypoxic rats for more than 3 h. The drug was also found to be effective in controlling the early stages of seizures following the anoxic insult. In contrast, the drug was ineffective in controlling either myoclonus or seizures in p,p'-DDT-treated animals. These results suggest that gabapentin can be used used as an effective therapeutic agent in an acute hypoxia/ischemia-induced neurological disorder. The data further indicate that distinct neurological mechanisms may be operating in the expression of myoclonus among posthypoxic and p,p'-DDT-induced animal models. 

GABA (gamma-aminobutyric acid); excitatory amino acid; seizure; ischemia; neurological disorder; drug screening; antiepileptic